BACKGROUND: TAVR has become an established treatment for severe symptomatic aortic stenosis in patients with high surgical risk. The latest generation of the balloon-expandable Edwards Sapien device, the Sapien 3, together with its new transfemoral Commander delivery system has been designed to reduce paravalvular regurgitation and vascular access site complications. OBJECTIVES: To evaluate procedural results and short term outcome with the third generation Sapien 3 device. METHODS: We retrospectively evaluated 125 consecutive TAVR patients and analyzed the first 51 patients in whom we implanted the new Sapien 3 device via transfemoral access. RESULTS: In patients implanted with the Sapien 3 device significant residual paravalvular regurgitation after TAVR was virtually absent with the vast majority having none or trace postinterventional aortic regurgitation on angiography or echocardiography (92.2% and 80.4% respectively). None of the patients had more than mild paravalvular regurgitation. Major vascular access site complications or major bleeding according to the VARC II criteria were not observed in our cohort, minor vascular complications and minor bleeding occurred in 7.8% and 5.9% respectively. If vascular complications occurred, they were related to closure device failure. Thirty day outcome showed a 1.9% major stroke rate and 3.9% death rate. However, we observed a 25.5% permanent pacemaker rate in our Sapien 3 cohort. CONCLUSIONS: Implantation of the new third generation Sapien 3 device resulted in excellent procedural and short term outcome. Significant paravalvular regurgitation was virtually absent. However, the increased rate of postinterventional pacemaker implantations needs to be analyzed in a larger cohort of patients.
BACKGROUND: TAVR has become an established treatment for severe symptomatic aortic stenosis in patients with high surgical risk. The latest generation of the balloon-expandable Edwards Sapien device, the Sapien 3, together with its new transfemoral Commander delivery system has been designed to reduce paravalvular regurgitation and vascular access site complications. OBJECTIVES: To evaluate procedural results and short term outcome with the third generation Sapien 3 device. METHODS: We retrospectively evaluated 125 consecutive TAVR patients and analyzed the first 51 patients in whom we implanted the new Sapien 3 device via transfemoral access. RESULTS: In patients implanted with the Sapien 3 device significant residual paravalvular regurgitation after TAVR was virtually absent with the vast majority having none or trace postinterventional aortic regurgitation on angiography or echocardiography (92.2% and 80.4% respectively). None of the patients had more than mild paravalvular regurgitation. Major vascular access site complications or major bleeding according to the VARC II criteria were not observed in our cohort, minor vascular complications and minor bleeding occurred in 7.8% and 5.9% respectively. If vascular complications occurred, they were related to closure device failure. Thirty day outcome showed a 1.9% major stroke rate and 3.9% death rate. However, we observed a 25.5% permanent pacemaker rate in our Sapien 3 cohort. CONCLUSIONS: Implantation of the new third generation Sapien 3 device resulted in excellent procedural and short term outcome. Significant paravalvular regurgitation was virtually absent. However, the increased rate of postinterventional pacemaker implantations needs to be analyzed in a larger cohort of patients.
Authors: Birgid Gonska; Julia Seeger; Mirjam Keßler; Alexander von Keil; Wolfgang Rottbauer; Jochen Wöhrle Journal: Clin Res Cardiol Date: 2017-03-10 Impact factor: 5.460
Authors: Costanza Pellegrini; Tobias Rheude; Teresa Trenkwalder; N Patrick Mayr; Michael Joner; Adnan Kastrati; Heribert Schunkert; Oliver Husser; Christian Hengstenberg Journal: Clin Res Cardiol Date: 2019-05-02 Impact factor: 5.460
Authors: Dritan Useini; Markus Schlömicher; Assem Aweimer; Peter Haldenwang; Justus Strauch; Polykarpos C Patsalis Journal: Gerontol Geriatr Med Date: 2022-01-19
Authors: Tobias Tichelbäcker; Leonard Bergau; Miriam Puls; Tim Friede; Tobias Mütze; Lars Siegfried Maier; Norbert Frey; Gerd Hasenfuß; Markus Zabel; Claudius Jacobshagen; Samuel Sossalla Journal: PLoS One Date: 2018-10-17 Impact factor: 3.240
Authors: Philipp Breitbart; Gregor Pache; Jan Minners; Manuel Hein; Holger Schröfel; Franz-Josef Neumann; Philipp Ruile Journal: Clin Res Cardiol Date: 2020-05-12 Impact factor: 5.460